Elkfork Partners’s AstraZeneca AZN Stock Holding History

Elkfork Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$724K	Buy	8,126 +3,247	+67%	+$282K	0.02%	474
2019 Q2	$403K	Buy	4,879 +765	+19%	+$60K	0.01%	641
2019 Q1	$333K	Buy	4,114 +867	+27%	+$68.3K	0.01%	671
2018 Q4	$247K	Sell	3,247 -6,426	-66%	-$502K	0.01%	714
2018 Q3	$766K	Hold	9,673	–	–	0.02%	456
2018 Q2	$679K	Buy	9,673 +544	+6%	+$39.1K	0.02%	443
2018 Q1	$638K	Hold	9,129	–	–	0.02%	462
2017 Q4	$634K	Hold	9,129	–	–	0.02%	469
2017 Q3	$619K	Hold	9,129	–	–	0.02%	439
2017 Q2	$622K	Hold	9,129	–	–	0.02%	437
2017 Q1	$569K	Hold	9,129	–	–	0.02%	424
2016 Q4	$499K	Buy	+9,129	New	+$518K	0.02%	411

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Elkfork Partners's AZN Position: Q3 2019 in Review

Elkfork Partners increased its AstraZeneca (AZN) stake by 67% in Q3 2019, buying an estimated $282K and bringing the position to 8,126 shares worth $724K. The position accounts for 0.02% of the portfolio, ranked #474.

Elkfork Partners first reported a position in AZN in Q4 2016 and has held it in 12 quarters since. The position peaked at $766K in Q3 2018. 555 funds tracked by Wall St. Rank hold AZN as of Q3 2019.

Elkfork Partners held 8,126 shares of AstraZeneca worth $724K as of Q3 2019.
Elkfork Partners bought 3,247 AstraZeneca shares in Q3 2019, an estimated $282K.
AstraZeneca made up 0.02% of Elkfork Partners's portfolio in Q3 2019, its #474 holding.
Elkfork Partners first reported a position in AstraZeneca in Q4 2016 and has held it in 12 quarters since.
Elkfork Partners's AstraZeneca position peaked at $766K in Q3 2018.
555 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2019.

Based on Elkfork Partners's 13F filing for Q3 2019, filed 14 Nov 2019.